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RESEARCH Open Access
Dexamethasone administration during
definitive radiation and temozolomide renders
a poor prognosis in a retrospective analysis of
newly diagnosed glioblastoma patients
Lisa B. E. Shields1,2, Brent J. Shelton3, Andrew J. Shearer3, Li Chen3, David A. Sun1,2, Sarah Parsons2,4,
T. David Bourne2, Renato LaRocca2,4 and Aaron C. Spalding2,4,5*
Abstract
Background: Dexamethasone (DXM) is commonly used in the management of cerebral edema in patients
diagnosed with glioblastoma multiforme (GBM). Bevacizumab (BEV) is FDA-approved for the progression or
recurrence of GBM but has not been shown to improve survival when given for newly diagnosed patients
concurrently with radiation (RT) and temozolomide (TMZ). Both DXM and BEV reduce cerebral edema, however,
DXM has been shown to induce cytokine cascades which could interfere with cytotoxic therapy. We investigated
whether DXM would reduce survival of GBM patients in the setting of concurrent TMZ and BEV administration.
Methods: We reviewed the treatment of all 73 patients with GBM who received definitive therapy at our institution
from 2005 to 2013 with RT (60 Gy) delivered with concurrent daily TMZ (75 mg/m2). Of these, 34 patients also were
treated with concurrent BEV (10 mg/kg every two weeks). Patients received adjuvant therapy (TMZ or TMZ/Bev)
until either progression, discontinuation due to toxicity, or 12 months after radiation completion. All patients who
had GBM progression with TMZ were offered BEV for salvage therapy, with 19 (56 %) receiving BEV.
Results: With a median follow-up of 15.6 months, 67 (91.8 %) patients were deceased. The OS for the entire cohort
was 15.9 months, while the PFS was 7.7 months. The extent of resection was a prognostic indicator for OS (p = .0044).
The median survival following gross tumor resection (GTR) was 22.5 months, subtotal resection (STR) was 14.9 months,
and biopsy was 12.1 months. The addition of BEV to TMZ with RT was borderline significantly associated with increased
PFS (9.4 vs. 5.1 months, p = 0.0574) although was not significantly associated with OS (18.1 vs. 15.3 months respectively,
p = 0.3064). In patients receiving TMZ, DXM use concurrent with RT was a poor prognostic indicator of both OS
(12.7 vs. 22.6 months, p = 0.003) and PFS (3.6 vs. 8.4 months, p <0.0001). DXM did not reduce OS in patients who
received TMZ and BEV concurrently with RT (22.9 vs 22.8 months, p = 0.4818). On multivariable analysis, DXM use
predicted an unfavorable OS hazard ratio (HR) = 1.72, p = 0.045).
Conclusions: Our results with TMZ, BEV, and RT are similar to previous studies in terms of PFS and OS. DXM use during
RT with concurrent TMZ correlated with reduced OS and PFS unless BEV was administered.
Keywords: Radiation, Oncology, Dexamethasone, Bevacizumab, Temozolomide, Glioblastoma multiforme,
Radiation, Survival
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Introduction
The treatment of patients with GBM poses a challenge
as the median patient survival rate after diagnosis is be-
tween 12 months with radiation alone and 14 ½ months
with radiation and TMZ [1]. Several factors play a role
in the prognosis of these patients, including age, pre-
operative performance status assessed by the Karnofsky
Performance Scale, and extent of resection [2–5]. Re-
section of 98 % or more of the tumor has been shown to
prolong survival in patients with GBM [4]. Furthermore,
residual tumor enhancement by immediate postoperative
MRI portends a significant reduction in survival as
patients with a residual tumor postoperatively had a
6.595-times higher risk of death in comparison to pa-
tients without a residual tumor [2].
TMZ has been shown to improve OS and PFS when
given concurrently with RT in newly diagnosed GBM
patients [1, 6–9]. Additionally, adjuvant TMZ after com-
pletion of RT is a positive prognostic indicator of im-
proved OS and PFS [1, 7–9]. As an alkylating agent,
TMZ induces O6-methylguanine DNA lesions leading to
apoptosis of tumor cells through mitochondrial activa-
tion of caspases in a Bcl-2 dependent mechanism [10].
In vitro, DXM protects GBM cells from TMZ-induced
apoptosis by inhibition of caspase cleavage and alteration
of bcl-2 levels [11]. Methylation status of the methyl-
guanine methyl transferase gene (MGMT) promoter has
been shown to be the strongest predictor for outcome
and benefit from TMZ chemotherapy [8]. Tumors that
do not express MGMT are more susceptible to che-
motherapy with alkylating drugs, while patients with
methylated MGMT promoter treated with TMZ and
radiotherapy have long-term PFS [8].
DXM is commonly used in the management of GBM
patients to treat intracranial edema and to control neuro-
logical symptoms, although there are no randomized trials
of DXM investigating effects on survival [12]. While DXM
may alleviate the negative symptoms that accompany
GBM, patients are often encouraged to taper their use of
DXM due to the side effects of hyperglycemia, osteopor-
osis, myopathy, weight gain, and immunosuppression
[13]. DXM use may be reduced through administration of
vascular endothelial growth factor (VEGF) inhibitors to
minimize brain edema [12]. BEV is a monoclonal antibody
that inhibits VEGF and may have a corticosteroid-sparing
effect in patients with recurrent GBM [12].
We report here the OS and PFS of 73 newly diagnosed
GBM patients with a focus on the effect of DXM with
and without BEV. This cohort consisted of two initial
regimens receiving identical RT: 1) concurrent and adju-
vant TMZ, and 2) concurrent and adjuvant TMZ and
BEV. This allowed us to study the interaction of DXM,
TMZ, and BEV on the OS and PFS of newly diagnosed
GBM patients.
Methods
Under an institutional IRB-approved protocol and in
compliance with the Helsinki Declaration, we retrospect-
ively reviewed the treatment of 73 patients with GBM
who received 30 fractions of simultaneous integrated
boost IMRT delivered either with concurrent and adju-
vant BEV and TMZ (combined, n = 34) or TMZ alone
(standard, n = 39). This study included all patients at
one center who were diagnosed with a GBM between
2005–2013. Our cohort spans an era prior to and
after the reporting of RTOG 0825 and AVAGlio studies
[14–16]. Patients prior to these studies received the com-
bined arm while those after received standard therapy
with BEV offered as salvage therapy in accordance with
FDA approval and then possible BEV at relapse.
The extent of resection (gross total, subtotal, or biopsy
only) was determined on 24-h postoperative MRI by a
radiologist blinded to the neurosurgeon’s perspective.
Preoperative and postoperative MRI scans were com-
bined with the radiation planning CT scan. A MRI scan
with gadolinium (GAD) was performed before initiation
of adjuvant therapy and every subsequent three months.
Radiation consisted of 30 identical fractions delivered
once daily five times per week. The planning target
volume prescribed 60 Gy (PTV60) received 2 Gy daily
to the tumor bed or residual tumor delineated with
T1 + GAD plus 1.5 cm margin while the planning target
volume prescribed 54 Gy (PTV54) received 1.8 Gy to the
T2 FLAIR +2.5 cm. The combined regimen consisted of
concurrent TMZ (75 mg/m^2) daily and BEV (10 mg/kg
every two weeks) administered during RT for six weeks.
One month after completion of RT, adjuvant TMZ
(150 mg/m^2 × 5 days) was delivered monthly with
BEV (10 mg/kg) every two weeks until progression, toxic-
ities, or 12 months total. The standard regimen involved
RT to 60 Gy with concurrent TMZ (75 mg/m^2) given
daily during RT for six weeks. One month after comple-
tion of RT, TMZ (150 mg/m^2 × 5 days) was delivered
monthly for up to 12 months. At the time of disease pro-
gression, all patients were offered BEV infusion every
three weeks as salvage therapy. A total of 19 patients re-
ceived salvage BEV after progression on the standard arm.
All patients received DXM during the perioperative
period which was weaned prior to the start of RT if pos-
sible. We categorized patients based on the use of DXM
during RT for this analysis. Patients who could not taper
off or who restarted DXM during RT were categorized
as positive for steroid usage.
Progression free time refers to the interval between
the diagnosis and progression. Progression was defined
as: (1) New T1 and gadolinium enhancement; (2) T2
FLAIR progression; (3) new or worsening neurological
symptoms; (4) a change in therapy; or (5) death. For pa-
tients receiving BEV, universally agreed criteria were
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used to determine progression [17]. The MRIs were in-
dependently reviewed by a neuroradiologist. The overall
survival time was defined as the interval between diag-
nosis and death from any cause.
Descriptive analyses were conducted to estimate patient
clinical and demographic characteristics. Kaplan-Meier ana-
lysis was performed to assess differences in event-free (pro-
gression and death) experience between groups using all
patients as well as between groups using subsets of patients
(eg. those only on TMZ). The log-rank test was invoked to
assess statistical significance in univariable comparisons
[18]. To adjust for potential covariate effects, Cox propor-
tional hazards regression was used as the modeling para-
digm [19]. Multivariate analysis was conducted using Cox
regression modeling. The proportional hazards assumption
was assessed both visually using plots of the observed stan-
dardized score process with 20 simulated realizations for
each covariate included in the model as well as quantita-
tively using the Kolmogorov-type supremum test based on
1000 simulations [20].
Results
Whole cohort observations: univariable analysis
A total of 73 patients were treated during this study with
an age range at diagnosis between 28 and 79 years (median
age 61 years) (Table 1). With a median follow-up of 15.6
months, 67 (91.8 %) patients were deceased. The average
age at death was 60.5 years (age range 30–81 years). Forty-
four patients (60 %) were male; 29 (40 %) were female. Two
patients died before completion of RT due to progression
after 6 Gy and 26 Gy, respectively. One patient developed a
wound infection during radiation and received only 16 Gy.
The median RT dose was 60 Gy. The majority (38; 52 %) of
patients underwent a GTR, while 24 (33 %) underwent a
STR and 11 (15 %) had a biopsy. Table 1 provides a descrip-
tion of this cohort of patients in terms of extent of resec-
tion, the concurrent regimen used, smoking, hypertension
(HTN), body mass index (BMI), diabetes mellitus (DM),
hyperlipidemia, and the use of DXM during RT. The OS
for the whole cohort was 15.9 months (Fig. 1a), while the
PFS was 7.7 months. The one-year and two-year survival
was 70 and 31 %, respectively. The extent of resection was
a prognostic indicator for OS (p = .0044) (Fig. 1b). The me-
dian survival following GTR was 22.6 months, STR was
14.9 months, and biopsy was 12.1 months. Patients who
underwent a biopsy for GBM had a poor prognosis for OS.
The addition of BEV to TMZ with RT was borderline sig-
nificantly associated with increased PFS (9.4 vs. 5.1 months,
p = 0.0574) although was not significantly associated with
OS (18.1 vs. 15.3 months respectively, p = 0.3064).
Influence of dexamethasone: univariable analysis
DXM use concurrent with RT was a poor prognostic indi-
cator of both OS (median 12.7 vs. 22.5 months, p = 0.02,
Fig. 1c) and PFS (median 6.0 vs. 8.8 months, p = 0.002) in
the whole cohort. Given the known significance of the
extent of resection on survival, we analyzed the effect
of DXM in patients with either a GTR (Fig. 1d) or
STR/Biopsy. For patients who underwent GTR, those
who were treated with DXM had a median survival of
16.3 months compared to 24.6 months without DXM
(p = 0.15). Patients who underwent either STR or biopsy
had nearly a two-fold reduction of median survival with
DXM administration (8.2 months) compared to those
without DXM (15.3 months) although statistical signifi-
cance was not reached (p = 0.20).
Since BEV has been shown to reduce the use of DXM,
we conducted additional analyses in patients who re-
ceived TMZ only during RT without BEV. In patients
receiving TMZ, DXM use concurrent with RT was a
poor prognostic indicator of both OS (12.7 vs. 22.6
months, p = 0.003, Fig. 2a) and PFS (3.6 vs. 8.4 months,
p < 0.0001). Even in patients who underwent a GTR
treated with TMZ alone, DXM use was a poor
Table 1 Population statistics of patients with newly
diagnosed GBM
Population statistics Category Absolute Percentage
Median age
at diagnosis
61.0
Average age
at death
60.5
Gender M 44 60 %
F 29 40 %
Extent of resection GTR 38 52 %
STR 24 33 %
Biopsy 11 15 %
Median RT dose 6000
Concurrent agents Temozolomide alone 39 53 %
Temozolomide and
Bevacizumab
34 47 %
Smoker No 43 60 %
Yes 29 40 %
HTN No 32 44 %
Yes 41 56 %
BMI Normal (<25) 17 23 %
Overweight (25–30) 37 51 %
Obese (>30) 19 26 %
DM No 63 86 %
Yes 10 14 %
Hyperlipidemia No 46 63 %
Yes 27 37 %
Dexamethasone
during RT
No 37 51 %
Yes 36 49 %
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prognostic factor for OS (13.5 vs 25.1 months, p = 0.01,
Fig. 2b). Interestingly, DXM did not reduce OS in pa-
tients who received TMZ and BEV concurrently with RT
(22.9 vs 22.8 months, p = 0.4818, Fig. 2c). DXM did not
affect PFS in patients receiving concurrent BEV with
TMZ (9.5 vs. 8.9 months, p = 0.6520).
Multivariable analysis
Cox proportional hazards regression modeling was used
to assess whether DXM administration continued to con-
fer unfavorable time-to-event (progression and death) as
seen in the univariable analyses. Two separate sets of mul-
tivariable models were run to supplement the respective
univariable analyses. One set included all patients in the
observation cohort. The second set included those admin-
istered only TMZ. In the first set of analyses (on the whole
cohort), models for OS and PFS included the following
covariate list: DXM, BEV, extent of resection, age at diag-
nosis, gender, XRT dosage, smoking status, and BMI. For
the whole cohort analysis, significant predictors of un-
favorable OS included patients with DXM (hazard ratio
(HR) = 1.72, p = 0.045) and decreasing XRT dosage (a 1 sd
decrease of 7.41 Gy results in HR = 1.66, p = 0.0035).
Extent of resection was borderline significant (Wald chi-
square p = 0.0617) for OS. Significant predictors of
unfavorable PFS included patients with DXM (HR = 2.98,
p = 0.0004) as well as patients without BEV (HR = 2.64,
p = 0.0015). Results using only those administered TMZ
were similar for OS to the whole cohort analysis: DXM
use resulted in an increase in hazard of death (HR = 2.87,
p = 0.0255) while decreasing XRT dosage by 1 sd
(7.41 Gy) resulted in an increase in hazard of death
(HR = 1.63, p = 0.0079). For PFS, DXM use was the only
covariate found to be significantly associated with less
favorable outcome (HR = 4.46, p = 0.0015).
There were no evidences for departure from the pro-
portional hazards assumption for any of the covariates
included in the models when inspecting the diagnostic
plots of the observed standardized model process plotted
over time. Additionally, all p-values associated with the
Kolmogorov-type supremum test, which quantitatively
tests for departures from proportional hazards, were not
significant.
Discussion
Several studies have investigated the combination of
BEV and TMZ with RT in the treatment of newly diag-
nosed GBM [1, 21–27]. Our results compare favorably
to these previous studies as the median OS, PFS, and
one- and two-year survival data for patients with GBM
who have been treated with a combination of RT and
chemotherapy following initial resection are presented in
Fig. 1 Kaplan-Meier curve shows the (a) OS of the whole cohort of newly diagnosed GBM patients after surgical resection, with a median of
15.9 months. b The extent of resection correlated with OS: GTR 22.6 months, STR 14.9 months, and biopsy 12.1 months. c DXM use concurrent
with RT was a poor prognostic indicator of OS (median 12.7 vs. 22.5 months, p = 0.02 by log-rank test). d For patients who underwent GTR, those
who were treated with DXM had a median survival of 16.3 months compared to 24.6 months without DXM (p = 0.15 by log-rank test)
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Table 2. Our results with TMZ and RT are similar to
previous studies in terms of PFS and OS. The OS for
our whole cohort was 15.9 months, while the PFS was
7.4 months. The one-year and two-year survival in our
study was 71 and 32 %, respectively. Concurrent BEV
and TMZ with RT was significantly associated with in-
creased PFS although was not significantly associated
with OS. Our study also confirms the known literature
that the extent of resection was a significant prognostic
indicator for OS. The median survival following GTR
was 22.5 months, STR was 14.93 months, and biopsy
was 12.1 months.
In Keth et al.’s study of 345 patients with newly
diagnosed GBM, they demonstrated that GTR was a
favorable prognostic factor for OS while the value of
incomplete resection remained questionable [28]. They
recommended biopsy only if GTR could not be safely per-
formed as biopsy provided acceptable histological diagno-
sis and determination of MGMT promoter methylation
status [28].
Fig. 2 Kaplan-Meier curve of the (a) DXM use concurrent with RT was a poor prognostic indicator of OS in patients receiving TMZ (12.7 vs 22.6
months, p = 0.003 by log-rank test). b DXM use was a poor prognostic factor for OS in patients who underwent a GTR treated with TMZ alone
(13.5 vs 25.1 months, p = 0.01 by log-rank test). c DXM did not reduce OS patients who received TMZ and BEV concurrent with RT (22.9 vs 22.8
months, p = 0.4818 by log-rank test)
Table 2 Survival for patients with GBM following radiation with biological agents
Study Treatment Median OS Median PFS One-year survival Two-year survival
Current study (2015) (n = 73) RT + BEV + TMZ (12 cycles) 15.9 months 7.7 months 70 % 31 %
Stupp [1] (n = 287) RT + TMZ 14.6 months 6.9 months 61 % 27 %
Grossman [19] (n = 244) RT + TMZ + novel agents 19.6 months – 81 % 37 %
Lai [21] (n = 70) RT + BEV + TMZ 19.6 months 13.6 months – –
Vredenburgh [24] (n = 75) RT + BEV + TMZ + Irinotecan 21.2 months 14.2 months 78.7 % 44.9 %
Narayana [22] (n = 51) RT + BEV + TMZ (six cycles) 23 months 13 months 85 % 43 %
OS Overall survival
PFS Progression-free survival
RT Radiotherapy
BEV Bevacizumab
TMZ Temozolomide
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Two eagerly anticipated phase III trials (Avaglio and
RTOG 0825) have focused on the upfront use of BEV with
TMZ and RT in newly-diagnosed GBM [14–16, 29]. Both
of these studies showed significantly prolonged PFS and
similar adverse effects of BEV, however, the interim analysis
of OS did not reach statistical significance [14–16, 30, 31].
The Avaglio study demonstrated maintenance of quality of
life outcomes, while RTOG 0825 showed a decreased
quality of life [14, 30, 31]. OS results from these two trials
do not support routine upfront BEV. Questions remain
whether BEV should be used to treat patients with recur-
rent GBM since it offers QOL and PFS benefits [31].
The Avaglio trial addressed the use of glucocorticoids
in patients who were treated with BEV [29]. Of the pa-
tients who received DXM at baseline, DXM was discon-
tinued in 66.3 % of patients who received BEV compared
to 47.1 % of patients receiving placebo. Furthermore, of
the patients who were not treated with DXM at baseline,
the time to initiation of DXM was significantly longer
with BEV than placebo [29]. Both of these observations
support the hypothesis that BEV reduces cerebral edema
to improve clinical symptoms.
DXM is commonly used in the treatment of GBM to
manage cerebral edema and has anti-inflammatory prop-
erties [11, 32]. It is often prescribed at diagnosis to de-
crease tumor-associated vasogenic edema and improve
symptoms [13]. DXM is often continued after biopsy or
resection to reduce post-operative edema and then con-
tinued during RT to decrease radiation-associated edema
[13]. DXM is occasionally utilized concurrently with
TMZ and RT after the initial surgical resection of a
GBM. It has been shown that DXM works as an antag-
onist on TMZ-induced apoptosis in human glioblastoma
T98G cells, suggesting that the combination of TMZ
and DXM may be counteractive in treating GBM [11].
Due to the toxicities associated with DXM, including
hyperglycemia, myopathy, osteoporosis, and immuno-
suppression, many patients with GBM decrease or dis-
continue their DXM use early in their management of
GBM [12, 13]. Contrarily, other patients may necessitate
an increase in DXM if they experience focal neurologic
symptoms (hemiparesis, visual field deficit, or aphasia)
or global symptoms (headache, nausea, or decreased
appetite) [13].
Cerebral edema is a common side effect of chemora-
diotherapy for GBM, necessitating glucocorticoid man-
agement [33]. Substantial deregulation of blood glucose
levels may ensue. In their study of 106 GBM patients,
Mayer et al. determined that one or more deregulated
blood glucose values > 10 mM was associated with a re-
duction in median OS from 16.7 to 8.8 months [33]. In
addition, a significantly poorer OS was found in patients
with hyperglycemia who underwent complete tumor
resection.
Several reports have demonstrated DXM dependency
during RT as an independent poor predictor of survival
in GBM [32, 34, 35]. In their study of 173 patients with
malignant gliomas, Watne et al. reported that patients
who were corticosteroid-dependent after craniotomy
had a 1.9 relative death risk as compared to patients
who were off steroids post-operatively [35]. They did not
examine whether the increased relative risk of death as-
sociated with corticosteroid use was influenced by the
extent of resection. Michaelsen et al. reported that the
use of corticosteroid therapy was significantly correlated
with patient survival and disease progression in their
study of 225 GBM patients [34]. Corticosteroid therapy
at TMZ and RT initiation had a significant negative
impact on OS (p < 0.0001). This study examined the
interaction of age with corticosteroid use but did not
investigate the interaction of extent of resection and cor-
ticosteroid use. Patients with a GTR would be expected
to have the longest OS. These data together demon-
strated that DXM administration produces shorter over-
all survival even without measurable contrast-enhancing
tumor, suggesting the effect is independent of the extent
of resection. We found by both univariate and multivari-
able analysis that DXM use correlated with decreased
OS. Thus, our data both reinforce previous work as well
as expand the conclusions to include the extent of resec-
tion along with DXM use.
Gorlia et al. analyzed the data from 300 patients with
recurrent GBM in eight phase I or II trials conducted by
the EORTC Brain Tumor Group [36]. A total of 138
patients received TMZ and RT followed by TMZ as
first-line therapy, while 158 patients received RT alone
or with another chemotherapy; four were treated with-
out previous radiotherapy [36]. They demonstrated that
patients who received TMZ and RT followed by TMZ
were significantly less often treated with baseline ste-
roids (57 % vs 73 %, p = 0.004). They concluded that
patients treated with steroids at baseline had a shorter
OS. Furthermore, they suggested that the use of anti-
angiogenic therapies may change the prognostic poten-
tial of certain factors, such as BEV administration may
reduce the detrimental effect of the need for steroids, at
least on PFS [36].
Vredenburgh et al. investigated the effect of corticoster-
oid use in GBM patients at first or second recurrence
treated with BEV in the BRAIN study [12]. The BRAIN
study was a phase II, multicenter, randomized trial of BEV
alone or concurrent with irinotecan (CPT-11) in patients
with recurrent GBM. The authors reported that the ma-
jority of patients who had an objective response or PFS > 6
months experience corticosteroid dose reduction. They
suggested that BEV may have a corticosteroid-sparing ef-
fect in patients with recurrent GBM and that a reduction
in corticosteroids may positively affect patient QOL [12].
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Our present study concurs with previous studies that
DXM use concurrent with RT is a significantly poor
prognostic indicator of both PFS and OS in patients with
GBM. Our study is the first in the literature, to our
knowledge, that investigated upfront DXM use concur-
rently with RT, TMZ, and BEV. In patients who received
TMZ, DXM use concurrent with RT was a poor prog-
nostic indicator of both OS and PFS. However, DXM did
not reduce OS or affect PFS in patients who received
TMZ and BEV concurrently with RT. In addition, of all
of the patients treated with DXM and RT, the OS was
significantly shorter in patients who only received TMZ
compared to those who received both TMZ and BEV.
Our results suggest that it is not recommended to treat
GBM patients with upfront DXM or with DXM concur-
rent with TMZ. However, if DXM is necessary due to
the negative side effects of GBM such as headaches, then
the administration of BEV concurrent with DXM may be
beneficial. We have shown that DXM use during RT
with concurrent TMZ correlated with reduced OS and
PFS unless BEV was administered.
Conclusion
The combination therapy of TMZ, BEV, and RT was safe
and well tolerated in this study. Similar to previous re-
ports in the literature, RT with concurrent BEV and
TMZ was significantly associated with increased PFS but
not OS. The present study demonstrates that DMX use
concurrent with RT and TMZ was a poor prognostic in-
dicator of both OS and PFS. Contrarily, DMX did not
reduce OS in patients who received TMZ and BEV con-
currently with RT. Upfront use of BEV may prove bene-
ficial in GBM patients who require DXM use and are
treated with concurrent TMZ and RT.
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